Human medicines European public assessment report (EPAR): Inaqovi, cedazuridine,decitabine, Leukemia, Myeloid, Date of ...
The benefits of Inaqovi were evaluated in an ongoing study involving 89 adults with newly diagnosed AML. Within the study patients were divided into two groups. For the first cycle of treatment, one group was given Inaqovi once daily for five days while …